Other News

CSL Behring To Present New Real-World Data on Outcomes Following Acute Coronary Syndrome at the American Heart Association (AHA) Virtual Scientific Sessions 2020

Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets KING OF PRUSSIA, Pa., Nov. 10, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that results of two separate analyses will be shared at this year’s American Heart Association (AHA) Scientific […]

Four-year results from patient-level meta-analysis confirm safety profile of Philips Stellarex .035” low-dose drug-coated balloon

Meta-analysis of two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced […]

6-Month Data From the Surmodics Avess™ AV Fistula DCB First-in-Human Study Presented at VIVA 2020

Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS […]

Ra Medical Systems Hosts Summit with Vascular Physicians to Monitor Progress on Next-Generation DABRA Catheter Design

CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces a one-day DABRA Summit, during which participants will have the opportunity to provide input on the design features and enhancements for the Company’s next-generation DABRA […]

Eko Raises $65 Million in Series C Funding to Close the Gap Between Virtual and In-Person Heart and Lung Care

Eko wants every patient with chronic cardiovascular disease to be one click away from their doctor OAKLAND, Calif.–(BUSINESS WIRE)–Eko, a cardiopulmonary digital health company, today announced $65 million in Series C funding led by Highland Capital Partners and Questa Capital, with participation from Artis Ventures, DigiTx Partners, NTTVC, 3M Ventures, […]

Acceleron Announces Clinical Trial Updates, Preclinical Presentation on Sotatercept in Pulmonary Arterial Hypertension at the 2020 American Heart Association (AHA) Scientific Sessions

– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – – Acceleron to host investor and analyst conference call and webcast with guest PAH […]

GE Healthcare, GenesisCare Partner to Tackle Two Biggest Health Burdens Globally, Deliver Improved Cancer and Cardiovascular Care to Patients Around the World

The multi-year strategic partnership will enable GenesisCare to offer patients greater access to leading technology, with a plan to explore further collaborations to improve cancer diagnosis, treatment and cardiovascular care The agreement is valued at more than USD 130 million over the next five years, including imaging technologies, digital solutions, […]

Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced two presentations highlighting gene editing as a potentially transformative therapeutic approach at the American Heart Association (AHA) Scientific Sessions 2020, taking place virtually November 13-17, 2020. Verve is developing one-time gene editing medicines […]

Stereotaxis Reports 2020 Third Quarter Financial Results

ST. LOUIS, Nov. 09, 2020 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2020. “Stereotaxis is pleased to report revenue growth with the successful installation of the first Genesis RMN® and […]